Tokyo, Sept. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062841) titled 'Relapse Rates, Treatment Patterns, and Adverse Events in Patients with Neuromyelitis Optica Spectrum Disorder: A Study Using a National Database' on Sept. 10.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Neuromyelitis optica spectrum disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To estimate the relapse-free rate and the incidence of serious infections among patients with neuromyelitis optica spectrum disorder.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who met the study definition of NMOSD during the study period
Key exclusion criteria - Patients who met the study definition of myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) within 180 days before the initial diagnosis date of NMOSD.
Patients who met the study definition of MOGAD or multiple sclerosis (MS) after the initial diagnosis date of NMOSD.
Target Size - 0
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 29 Day
Date of IRB - 2026 Year 02 Month 05 Day
Anticipated trial start date - 2026 Year 11 Month 10 Day
Last follow-up date - 2027 Year 01 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071941
Disclaimer: Curated by HT Syndication.
